I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting

SHANGHAI and GAITHERSBURG,Md.,Oct.5,2021 -- I-Mab (Nasdaq: IMAB),a clinical-stage biopharmaceutical company committed to the discovery,development,and commercialization of novel or highly differentiated biologics,and ABL Bio,Inc. (Kosdaq:298380,hereafter "ABL"),a South Korean biotech specializing in bispecific antibody technology,jointlyannounced that data from the preclinical studies of TJ-CD4B/ABL111 and TJ-L14B/ABL503,will be presented at the Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021),taking place November 12 – 14,2021.

Developed in collaboration with ABL,TJ-CD4B/ABL111 and TJ-L14B/ABL503 are part of I-Mab's highly differentiated bispecific antibody pipeline that target the 4-1BB co-stimulatory molecule on T-cells and mount an anti-tumor response. Both target a highly specific epitope on 4-1BB,which results in localized action and reduced systemic toxicity.

TJ-CD4B/ABL111 engages the Claudin18.2 (CLDB18.2) tumor antigen mainly on gastric and pancreatic cancers to produce localized T-cell activation at the cancer site. It has demonstrated a strong affinity to CLDN18.2-positive cancer cells even at low levels of CLDN18.2 and has potential application in a wide range of cancers. TJ-CD4B/ABL111is currently undergoing phase 1 trials in the U.S. (NCT04900818) and soon will be in China,in patients with advanced solid tumors,including gastric cancers.

TJ-L14B/ABL503 is a novel bi-specific antibody targeting both PD-L1 and 4-1BB. It engages the PD-L1 molecule on cancer cells and exerts a strong anti-tumor activity through localized activation of T-cells and it is designed to overcome the limited efficacy of anti-PD-L1 therapies and anti-4-1BB-related toxicity. TJ-L14B/ABL503 is currently undergoing a phase 1 clinical trial in the U.S. (NCT04762641) in patients with locally advanced or metastatic solid tumors.

Details of the poster discussion session are as follows:

Abstract Number: 702

Title: TJ-CD4B (ABL111),a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies

Poster Session: Poster hall,12-14th November 2021,7.00 am-5.00 pm

Presenter: Dr. Wenqing Jiang,I-Mab

Abstract Number: 892

Title: ABL503 (TJ-L14B),PD-L1x4-1BB bispecific antibody induces superior anti-tumor activity by PD-L1-dependent 4-1BB activation with the increase of 4-1BB+CD8+ T cells in tumor microenvironment

Poster Session: Poster Hall,7.00am-5.00pm

Presenter: Dr. Gihoon You,ABL Bio